Rigel Pharmaceuticals, Inc. (USD) Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc. (USD) Active

611 Gateway Boulevard, South San Francisco, CA, US, 94080

Stock Price USD

Price Change

Last Dividend USD

A-

Latest Rating

RIGL's stock peer is AKBA (Akebia Therapeutics, Inc.)

RIGL's stock peer is BCYC (Bicycle Therapeutics plc)

RIGL's stock peer is CRVS (Corvus Pharmaceuticals, Inc.)

RIGL's stock peer is FDMT (4D Molecular Therapeutics, Inc.)

RIGL's stock peer is GOSS (Gossamer Bio, Inc.)

RIGL's stock peer is KALV (KalVista Pharmaceuticals, Inc.)

RIGL's stock peer is OLMA (Olema Pharmaceuticals, Inc.)

RIGL's stock peer is OMER (Omeros Corporation)

RIGL's stock peer is PRTA (Prothena Corporation plc)

RIGL's stock peer is VTYX (Ventyx Biosciences, Inc.)

Healthcare Biotechnology

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

20%

Dcf Rating

100%

Return On Equity

100%

Return On Assets

60%

Debt To Equity

60%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions.

2026-06-16 16:01:00

Rigel to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m.

2026-05-27 08:05:00

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster session Real-world data further supports the use of REZLIDHIA ® (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclax SOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 29, 2026.

2026-05-21 17:17:00

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m.

2026-05-14 08:05:00

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical trial results showed that vepdegestrant was generally well tolerated and reported mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement, in patients with 2L+ ER+/HER2- mBC with an ESR1 mutation Upon closing of the transaction, VEPPANU will become Rigel's fourth commercial product and its major focus to accelerate revenue growth while leveraging the company's existing infrastructure, contributing meaningfully to the advancement of Rigel's transformational growth strategy Arvinas and Pfizer will receive an upfront $70.0 million and an additional $15.0 million upon the successful completion of certain transition activities, and are eligible for up to $320.0 million in future potential regulatory and commercial milestones Rigel to host a conference call today at 8:00 a.m.

2026-05-12 07:00:00

Rigel Reports First Quarter 2026 Financial Results

First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated $8.7 million of net income in the first quarter of 2026 On track to complete enrollment in the dose expansion phase of the Phase 1b study evaluating R289 and select the recommended Phase 2 dose in the second half of 2026 2026 Outlook: Total revenues of approximately $275 to $290 million, which includes net product sales of $255 to $265 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

2026-05-05 16:01:00

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.

2026-04-28 08:05:00

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

2026-04-07 08:05:00

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW study evaluating pralsetinib for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) in the Journal of Clinical Oncology.

2026-03-31 08:05:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions